Literature DB >> 24062011

Positive airway pressure therapy in patients with opioid-related central sleep apnea.

Anthony Troitino1, Nawman Labedi, Thomas Kufel, Ali A El-Solh.   

Abstract

PURPOSE: This study aims to compare treatment response and adherence rate to positive airway pressure (PAP) in patients with opioid-related central sleep apnea (O-CSA) and idiopathic central sleep apnea (I-CSA).
METHODS: We performed a retrospective chart over a 5-year period performed at a VA sleep center. Continuous PAP (CPAP) was prescribed initially for all participants. For those nonresponders (apnea hypopnea index (AHI) of >10/h), bi-level PAP (BiPAP) or adaptive servoventilation (ASV) was instituted upon provider's discretion. Adherence to therapy was checked with the built-in meter.
RESULTS: Thirty-four patients with O-CSA and 61 with I-CSA were included in the analysis. The two groups were comparable with respect to age, body mass index (BMI), Epworth Sleepiness Scale, and burden of comorbidities. The mean daily equivalent dose of morphine in the O-CSA was 168 mg (range 30-1,217 mg). In the O-CSA group, 24% of PAP-naïve patients responded to CPAP compared to 38% in the I-CSA group. BiPAP and ASV were comparable in eliminating central events in both O-CSA (66 versus 60 %) and I-CSA (93 versus 90%), respectively. Eight patients (24%) with O-CSA and six patients (10%) with I-CSA were considered nonresponders. The adherence rate was 48 and 24% in the I-CSA group compared to 23 and 18% in the O-CSA group at 3 and 12 months following initiation of effective treatment (p = 0.04 and p = 0.6).
CONCLUSIONS: The presence of O-CSA does not preclude an adequate response to CPAP. Adherence rate to PAP was poor in both the O-CSA and I-CSA groups. Further studies are needed to define optimal adherence rate and long-term benefits of PAP in CSA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24062011     DOI: 10.1007/s11325-013-0894-4

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  26 in total

Review 1.  Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force.

Authors: 
Journal:  Sleep       Date:  1999-08-01       Impact factor: 5.849

2.  Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: a prospective, observational study.

Authors:  Laxmaiah Manchikanti; Kim S Damron; Carla D McManus; Renee C Barnhill
Journal:  Pain Physician       Date:  2004-10       Impact factor: 4.965

Review 3.  Opioid guidelines in the management of chronic non-cancer pain.

Authors:  Andrea M Trescot; Mark V Boswell; Sairam L Atluri; Hans C Hansen; Timothy R Deer; Salahadin Abdi; Joseph F Jasper; Vijay Singh; Arthur E Jordan; Benjamin W Johnson; Roger S Cicala; Elmer E Dunbar; Standiford Helm; Kenneth G Varley; P K Suchdev; John R Swicegood; Aaron K Calodney; Bentley A Ogoke; W Stephen Minore; Laxmaiah Manchikanti
Journal:  Pain Physician       Date:  2006-01       Impact factor: 4.965

4.  Opioid-associated central sleep apnea: a case series.

Authors:  M A Alattar; S M Scharf
Journal:  Sleep Breath       Date:  2008-09-20       Impact factor: 2.816

Review 5.  Practice parameters for the indications for polysomnography and related procedures: an update for 2005.

Authors:  Clete A Kushida; Michael R Littner; Timothy Morgenthaler; Cathy A Alessi; Dennis Bailey; Jack Coleman; Leah Friedman; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Teofilo Lee-Chiong; Daniel L Loube; Judith Owens; Jeffrey P Pancer; Merrill Wise
Journal:  Sleep       Date:  2005-04       Impact factor: 5.849

6.  Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure.

Authors:  H Teschler; J Döhring; Y M Wang; M Berthon-Jones
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

7.  Adaptive servoventilation in patients with central or complex sleep apnea related to chronic opioid use and congestive heart failure.

Authors:  Kannan Ramar; Priya Ramar; Timothy I Morgenthaler
Journal:  J Clin Sleep Med       Date:  2012-10-15       Impact factor: 4.062

8.  Reversal of central sleep apnea using nasal CPAP.

Authors:  F G Issa; C E Sullivan
Journal:  Chest       Date:  1986-08       Impact factor: 9.410

9.  Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids.

Authors:  Shahrokh Javaheri; Athar Malik; Jason Smith; Eugene Chung
Journal:  J Clin Sleep Med       Date:  2008-08-15       Impact factor: 4.062

10.  A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure.

Authors:  Justin C T Pepperell; Nick A Maskell; David R Jones; Beverley A Langford-Wiley; Nicky Crosthwaite; John R Stradling; Robert J O Davies
Journal:  Am J Respir Crit Care Med       Date:  2003-08-19       Impact factor: 21.405

View more
  6 in total

1.  Positive airway pressure treatment for opioid-related central sleep apnea, where are we now?

Authors:  David Wang; Luke Rowsell; Brendon J Yee
Journal:  Sleep Breath       Date:  2013-10-26       Impact factor: 2.816

2.  Effect of opioids on sleep and breathing in chronic pain patients.

Authors:  M Jeffery Mador; Jennifer Henderson
Journal:  J Clin Sleep Med       Date:  2014-08-15       Impact factor: 4.062

Review 3.  Positive airway pressure therapy for heart failure.

Authors:  Takao Kato; Shoko Suda; Takatoshi Kasai
Journal:  World J Cardiol       Date:  2014-11-26

Review 4.  Medium Increased Risk for Central Sleep Apnea but Not Obstructive Sleep Apnea in Long-Term Opioid Users: A Systematic Review and Meta-Analysis.

Authors:  Marie-Lou Filiatrault; Jean-Marc Chauny; Raoul Daoust; Marie-Pier Roy; Ronald Denis; Gilles Lavigne
Journal:  J Clin Sleep Med       Date:  2016-04-15       Impact factor: 4.062

5.  Comparison of Therapeutic Approaches to Addicted Patients with Central Sleep Apnea.

Authors:  Christoph Schoebel; Amir Ghaderi; Babak Amra; Forogh Soltaninejad; Thomas Penzel; Ingo Fietze
Journal:  Tanaffos       Date:  2018-03

6.  Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Authors:  Andrew S Huhn; Patrick H Finan
Journal:  Exp Clin Psychopharmacol       Date:  2021-06-10       Impact factor: 3.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.